Navigation Links
Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
Date:4/24/2012

ent exchange rates, changes in foreign currency are expected to reduce otherwise reported sales growth by approximately 2% compared to the prior year. 
  • The recent acquisitions of BioReliance and Research Organics are expected to increase sales by approximately 6%. 
  •  

  • Diluted adjusted EPS forecast for 2012 (excluding any new restructuring charges, transaction costs associated with acquisitions and other one time charges) is expected to be $3.90 to $4.05, unchanged from our previous outlook. 
  • This outlook includes an approximate $0.10 reduction in otherwise reportable diluted EPS when compared to 2011 due to changes in foreign currency exchange rates.  Also reflected in this outlook is a higher anticipated effective tax rate of 30% to 31% in 2012 which will reduce otherwise reportable diluted EPS by approximately $0.10 when compared to 2011.
  • The acquisitions of BioReliance and Research Organics are expected to add approximately $0.05 to $0.07 to our diluted EPS in 2012. 
  • This outlook also includes the amortization of intangibles associated with acquisitions of $0.15 per diluted share in 2012 compared to $0.07 per diluted share in 2011.  This amortization is likely to reduce otherwise reportable operating margin by approximately 50 basis points in 2012.
  • We constantly evaluate changes in our markets and macroeconomic factors and will make appropriate adjustments to our cost structure in ways that will enable us to deliver on our commitments.
  •  

  • Free cash flow for 2012 is expected to be approximately $425 million, up from $400 million in our previous outlook.
  • Net cash provided by operating activities is expected to be approximately $550 million.
  • Capital expenditures are expected to be approximately $125 million.
  •  

    OTHER INFORMATION:

    Cash Flow and Debt:  Net cash provided by opera
    '/>"/>

    SOURCE Sigma-Aldrich
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related medicine technology :

    1. CRF Institute Names Sigma-Aldrich Top Employer Europe 2012
    2. Sigma-Aldrich Enhances Asia-Pacific Customer Support With New Distribution and Packaging Capabilities in India
    3. Sigma-Aldrich Corporation Will Hold Its Business Review March 29, 2012
    4. Sigma-Aldrich (Nasdaq:SIAL) Declares Increased Quarterly Dividend
    5. Sigma-Aldrich Completes Acquisition of BioReliance
    6. Avista Capital Partners Agrees to Sell BioReliance to Sigma-Aldrich Corporation
    7. Sigma-Aldrich Corporation to Present at Upcoming Investor Conference
    8. Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81.
    9. Sigma-Aldrich Corporation to Present at Upcoming Investor Conferences
    10. Sigma-Aldrich (NASDAQ:SIAL) Declares Quarterly Dividend
    11. Sigma-Aldrich Opens European Headquarters in St. Gallen, Switzerland
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/28/2015)...  Champions Oncology, Inc. (OTC: CSBR), engaged in the ... the development and use of oncology drugs, today announced ... 2015. Fourth Quarter and Recent Business Highlights: ... prior year period result , Procured a quarterly ... Joel Ackerman, Champions Oncology CEO, stated, "The end of ...
    (Date:7/28/2015)... 28, 2015  Roche (SIX: RO, ROG; OTCQX: ... for Clinical Chemistry (AACC) 2015 Clinical Lab Expo ... and a unique educational initiative that demonstrates how ... value of the laboratory. The new ... empower laboratories and the people within them through ...
    (Date:7/28/2015)... and HOUSTON, TX , July 28, 2015 ... EPIX ) is pleased to announce that it has received ... commence trading on the Toronto Stock Exchange (the "TSX"). The ... trading on Tuesday, July 28, 2015 under the trading symbol ... TSX Venture Exchange. About ESSA Pharma Inc. ...
    Breaking Medicine Technology:Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 2Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 3Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 4Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 5Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 6Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 7Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 8Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 9Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 10Champions Oncology Reports Results for Quarter and Full Year Ended April 30, 2015 11Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 2Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 3Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 4ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 2ESSA Pharma Inc. to Commence Trading on the Toronto Stock Exchange 3
    ... Inc. (NASDAQ: ARNA ) today announced that Robert ... Vice President, Finance and Chief Financial Officer. Mr. Hoffman served ... before departing in March to work for a private biopharmaceutical ... been a key contributor to Arena," said Jack Lief, Arena,s ...
    ... 2011 / PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: ... commercializing products targeting the extracellular matrix , today ... 2011 Life Sciences Conference in New York. The presentation ... EDT (6:10 a.m. PDT). To listen to the live ...
    Cached Medicine Technology:Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 2Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer 3Halozyme Therapeutics to Present at the Wedbush 2011 Global Healthcare Conference on August 17 2
    (Date:7/28/2015)... Boston, MA (PRWEB) , ... July 28, 2015 , ... ... developing cancer. One reason is that cancer, heart attack, and stroke are treatable, but ... One thing individuals can do is to take part in a clinical trial, reports ...
    (Date:7/28/2015)... ... July 28, 2015 , ... The ... Attack, Sudden Death, or Angina), many of whom are missed by conventional evaluation ... individuals with active yet undetected sub-clinical disease, who are at risk of experiencing ...
    (Date:7/28/2015)... ... July 28, 2015 , ... For more than two ... based its selection process on the foundation of peer nominations. Physicians nominate other ... any area of medicine and in any part of the country. Physicians cannot ...
    (Date:7/28/2015)... ... July 28, 2015 , ... One ... including Runner’s World Magazine, is plantar fasciitis . Zensah, the Miami-based compression ... Designed by a professional athletic trainer, the Zensah Ankle Support’s primary benefits include ...
    (Date:7/28/2015)... ... , ... Nurses across all settings increasingly provide care to people with mental ... mental health services (SAMHSA, 2013) and the implementation of the Affordable Care Act is ... the largest workforces who provide care to persons with mental health disorders. Providing this ...
    Breaking Medicine News(10 mins):Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3Health News:Utility of a novel coronary artery disease biomarker algorithm in modifying physician adherence to guideline therapy presented at 20th World Congress on Heart Disease 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 2Health News:Fort Myers Plastic Surgeon Recognized as One of the America’s “Top Doctors®” by Prestigious Castle Connolly Medical Ltd. for 5 Years in a Row 3Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 2Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 3Health News:American Psychiatric Nurses Association Transitions in Practice Certificate Program to Improve Mental Health Care Through Continuing Nursing Education 4
    ... being circulated in South Asia for various ailments like malaria, ... a British doctor in Laotian capital, Vientiane, the drugs have ... find out. ,World Health Organization states that majority ... been treated with the original drug. They also add that ...
    ... the makers of ADHD drugs to indicate the contra indications ... cardiovascular risks. ,Dr. Steven Galson, director of the ... these drugs are immensely useful in treating patients with ADHD, ... He also said that FDA is working in tandem ...
    ... of your wedding celebration. The world-renowned research and care center ... save lives of cancer patients. Couples getting married are encouraged ... Jimmy Fund. Dana-Farber treats both children and adults, and is ... ,A package of 10 table cards, gift cards, or ...
    ... about that shared experience are likely more satisfied with ... of experience to draw on, according to research by ... ,The study, conducted by Doris G. Bazzini and three ... issue of the journal Motivation and Emotion. ...
    ... Mukesh Haikerwal, today congratulated the Victorian Government on introducing ... child carers are trained in handling potentially deadly severe ... anaphylaxis program to be implemented nationally. ... to protect the children who suffer from severe allergies, ...
    ... who become impotent after prostate cancer surgery may find reprieve ... penis,// which assists in restoring the lost erectile function, according ... came to light after a study of nearly 44 patient ... function, following its loss after treatment for prostate cancer. ...
    Cached Medicine News:Health News:Researcher Studies Benefits of Reminiscing About Laughter 2Health News:National Plan Needed for Severe Allergy Kids 2
    Open blade speculum designed for both temporal and superior approach ocular surgery. Thumb screw adjusting mechanism. Manufactured in titanium....
    Adjustable lid speculum angled 45 degrees with 17 mm curved solid blades and aspiration ports to remove excess fluid from around the eye during ocular procedures....
    Open 15 mm blades allow intraocular manipulation without metal to metal contact. 16 mm lifting wings. Dull finish....
    Angled for temporal approach. Solid 14 mm blades. Dull finish....
    Medicine Products: